Annual Product Quality Review (APQR) Checklist [FREE PDF]

The Annual Product Quality Review (APQR), also known as the Annual Product Review (APR), is a mandatory requirement under FDA 21 CFR 211.180(e) and EU GMP Chapter 1, requiring manufacturers to conduct a yearly review of each drug product to assess the need for changes in specifications or manufacturing processes. The APQR must evaluate batch data, out-of-specification results, complaints, returns, stability results, and process capability to confirm the product consistently meets its registered

Industry: Pharmaceutical Manufacturing
Frequency: Annually
Estimated Time: 90-120 minutes
Role: QA Analyst
Total Items: 36
Compliance: FDA 21 CFR 211.180(e) - Annual product review requirements, ICH Q7 Section 1.5 - Annual product reviews for APIs, EU GMP Chapter 1 Section 1.10 - Product Quality Review, WHO GMP Guidelines TRS 986 Annex 2 - Annual product quality review, FDA 21 CFR Part 11 - Electronic records and audit trail requirements

Batch Production and Release Data Review

Compile and assess all batch production data including yields, batch failures, and rejections for the review period.

Has the total number of batches manufactured, released, rejected, and pending release been compiled for the review period?
Have batch yield data been analyzed and compared against established yield limits and historical trends?
Have any batch failures or rejected batches been identified and root causes documented?
Is process capability (Cpk) or equivalent statistical analysis available for critical quality attributes (CQAs)?
Has a trend analysis been performed on key in-process and finished product test results across all batches?

Out-of-Specification and Out-of-Trend Results

Review all OOS and OOT results generated during the review period for completeness of investigation and CAPA closure.

Has the total number of OOS results (laboratory and manufacturing) for the review period been compiled?
Have all OOS investigations been closed with documented root cause, CAPA, and effectiveness verification?
Have out-of-trend (OOT) results been identified through statistical trending and formally reviewed?
Are recurring OOS or OOT trends linked to a formal CAPA with defined timelines and ownership?
Has the ratio of OOS results to total tests performed been calculated and compared against the prior year?

Stability Program Data Review

Evaluate ongoing and long-term stability data to confirm the product continues to meet expiry specifications.

Has at least one batch per year been placed on the ongoing stability program per the approved stability protocol?
Are all stability time points for the review period completed, with no missed or overdue samples?
Have all stability OOS or OOT results been investigated and resolved with documented CAPA?
Does the stability data confirm that the product continues to meet specifications through the approved shelf life?
Has a shelf life extension or reduction been evaluated based on the current stability data trends?

Complaints, Returns, and Recalls

Review all customer complaints, product returns, and any recall activities for the review period.

Has the total number of customer complaints received during the review period been compiled and categorized?
Have all complaints been investigated, closed, and assessed for product quality impact and regulatory reportability?
Have complaint trend data been analyzed to detect any recurring product quality signals?
Have all product returns during the review period been assessed for product quality and safety implications?
Were any recalls or market withdrawals initiated during the review period, and if so, are all corrective actions documented and closed?

Change Control and Deviation Review

Summarize all changes and deviations implemented during the review period and assess their cumulative impact on product quality.

Have all change controls initiated or closed during the review period been compiled and categorized (major/minor/administrative)?
Have regulatory submissions (CBE, PAS, or equivalent) been filed for all major changes requiring prior approval?
Have all manufacturing deviations for the review period been compiled, investigated, and closed?
Have recurring deviation types been identified and linked to systemic CAPA actions with verified effectiveness?
Has the cumulative impact of all changes and deviations on product quality been formally assessed and documented?

Starting Materials and Supplier Quality Review

Evaluate the quality performance of raw material suppliers and the conformance of incoming materials during the review period.

Have all approved suppliers used during the review period been reviewed for quality performance (OOS, complaints, CAPA)?
Have incoming raw material test results been reviewed for OOS, OOT, or identity failures?
Has any change in API source, grade, or supplier been documented through the change control system?
Are all critical raw material and API suppliers currently on the approved supplier list with valid audit records?
Have any raw material-related deviations or investigations been linked back to specific supplier quality issues?

APQR Conclusions, CAPA, and Approval

Document overall conclusions, identify actions required, and obtain formal approval from responsible quality personnel.

Does the APQR conclude that the product has been consistently manufactured within its approved specifications throughout the review period?
Have all identified CAPA items been entered into the CAPA tracking system with owners and due dates assigned?
Has the APQR been reviewed and approved by the Head of Quality or equivalent responsible person?
Has the completed APQR been retained as a GMP record with appropriate access controls and archiving per data retention requirements?
Has the APQR been completed within the defined internal timeline (typically within 60 days of the review period end)?
Has the prior year APQR been reviewed to verify that all previously identified CAPA actions have been completed and are effective?

Related Pharmaceutical Checklists

Related Quality Control Checklists

Why Use This Annual Product Quality Review (APQR) Checklist [FREE PDF]?

This annual product quality review (apqr) checklist [free pdf] helps pharmaceutical manufacturing teams maintain compliance and operational excellence. Designed for qa analyst professionals, this checklist covers 36 critical inspection points across 7 sections. Recommended frequency: annually.

Ensures compliance with FDA 21 CFR 211.180(e) - Annual product review requirements, ICH Q7 Section 1.5 - Annual product reviews for APIs, EU GMP Chapter 1 Section 1.10 - Product Quality Review, WHO GMP Guidelines TRS 986 Annex 2 - Annual product quality review, FDA 21 CFR Part 11 - Electronic records and audit trail requirements. Regulatory-aligned for audit readiness and inspection documentation.

Frequently Asked Questions

What does the Annual Product Quality Review (APQR) Checklist [FREE PDF] cover?

This checklist covers 36 inspection items across 7 sections: Batch Production and Release Data Review, Out-of-Specification and Out-of-Trend Results, Stability Program Data Review, Complaints, Returns, and Recalls, Change Control and Deviation Review, Starting Materials and Supplier Quality Review, APQR Conclusions, CAPA, and Approval. It is designed for pharmaceutical manufacturing operations and compliance.

How often should this checklist be completed?

This checklist should be completed annually. Each completion takes approximately 90-120 minutes.

Who should use this Annual Product Quality Review (APQR) Checklist [FREE PDF]?

This checklist is designed for QA Analyst professionals in the pharmaceutical manufacturing industry. It can be used for self-assessments, team audits, and regulatory compliance documentation.

Can I download this checklist as a PDF?

Yes, this checklist is available as a free PDF download. You can also use it digitally in the POPProbe mobile app for real-time data capture, photo documentation, and automatic reporting.